Every Form 4 that Biofrontera Inc. Warrants (BFRIW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BFRIW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BFRIW filings page.
Biofrontera Inc. CEO and Chairman Hermann Luebbert converted 62,500 restricted stock units (RSUs) into 62,500 shares of common stock on July 28, 2026. These RSUs are part of a 125,000-unit award granted on July 22, 2025, vesting in two equal yearly installments beginning July 22, 2026. After the conversion, he directly held 352,711 shares of common stock and 62,500 RSUs from this grant, with RSUs having different terms expressly excluded.
Biofrontera Inc. Chief Financial Officer Eugene Frederick Leffler converted 31,250 restricted stock units into 31,250 shares of common stock on July 28, 2026 through an exercise of derivative securities. After this settlement, he directly holds 206,250 shares of Biofrontera common stock.
Biofrontera Inc. director Kevin Daniel Weber reported receiving an employee stock option grant to acquire 20,000 shares of the company’s stock. The option carries an exercise price of $0.00 per share and represents a new award, bringing his total directly held derivative securities from this grant to 20,000 options.
According to the disclosure, the option vests in twelve equal monthly installments beginning on April 4, 2026, meaning the right to exercise will phase in over one year. The filing notes that other options with different terms are not included in this reported transaction.
Biofrontera Inc. CEO and Chairman Hermann Luebbert reported several equity awards and an option-related share conversion. On March 4, 2026, he received 125,000 restricted stock units and an employee stock option for 125,000 shares, both at a price of $0.00 per unit or option. The restricted stock units vest in two equal yearly installments beginning on March 4, 2027, and may be settled in shares, cash, or a combination within 60 days of each vesting date. The option vests in two equal installments on September 4, 2026 and March 4, 2027. On March 5, 2026, 137,500 restricted stock units were exercised or converted into 137,500 shares of common stock at $0.00 per share, bringing his directly held common stock to 290,211 shares after the transaction.
Biofrontera Inc. Chief Financial Officer Eugene Frederick Leffler reported equity compensation activity, mainly awards and a derivative conversion. On March 4, 2026, he received 62,500 restricted stock units and 62,500 employee stock options, both granted for no cash consideration.
On March 5, 2026, 87,500 restricted stock units were converted into 87,500 shares of common stock at a price of $0.00 per share, leaving him with 175,000 common shares held directly after the transaction.
Lanckriet Heikki reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Heikki Lanckriet received a grant of employee stock options covering 20,000 shares on March 4, 2026. These options were awarded at a stated price of $0.0000 per share and represent a new direct derivative holding of 20,000 options.
The option grant vests in twelve equal monthly installments, beginning on April 4, 2026, spreading the benefit to the director over one year. The disclosure notes that options with different terms are not included in this reported amount.
Biofrontera Inc. reported that Chief Commercial Officer George Patrick Jones acquired new equity-based compensation. He received 50,000 restricted stock units, each representing a contingent right to one share of BFRI common stock awarded for no consideration.
He also received an option for 50,000 shares with a grant price of $0.00. The option vests in two equal installments on September 4, 2026 and March 4, 2027. The restricted stock units vest in two equal yearly installments beginning March 4, 2027, and each vested unit will be settled in shares, cash, or a combination within 60 days at the company’s discretion.